     |
   |
|
|
WATERTOWN, Massachusetts, USA, October 8, 2008 — Selecta Biosciences, a biopharmaceutical company pioneering in the discovery and development of targeted immunomodulatory nanoparticle drugs and vaccines, today announced the formation of its Scientific Advisory Board.
Robert Langer, ScD (Co-Founder and Scientific Advisory Board Co-Chair) — Drug delivery technology
Institute Professor, Massachusetts Institute of Technology, National Academy of Science USA, National Academy of Engineering, USA, Institute of Medicine, USA
Ulrich von Andrian, MD, PhD (Co-Founder and Scientific Advisory Board Co-Chair) — Immunology and leukocyte biology
Mallinckrodt Professor of Immunopathology, Harvard Medical School
Omid Farokhzad, MD (Co-Founder) — Targeted nanoparticle engineering
Assistant Professor, Harvard Medical School and Brigham and Women's Hospital
Rafi Ahmed, MD — Anti-viral immunity
Georgia Research Alliance Professor of Microbiology and Immunology, Emory University School of Medicine
Glenn Dranoff, MD — Tumor immunology
Associate Professor of Medicine, Brigham and Women's Hospital, Harvard Medical School
Peter M. Howley, MD — Virology
Shattuck Professor of Pathological Anatomy and Chair, Department of Pathology, Harvard Medical School, National Academy of Science, USA
Dennis Kasper, MD — Bacterial infectious diseases
William Ellery Channing Professor of Medicine, Director of the Channing Laboratory, Harvard Medical School, Institute of Medicine, USA
Alexander Klibanov, PhD — Protein enzymology and polymeric drug delivery
Professor of Chemistry and Bioengineering, Massachusetts Institute of Technology, National Academy of Science, USA
Klaus Rajewsky, MD — B-cell immunology
Fred S. Rosen Professor of Pediatrics, CBRI, Harvard Medical School, National Academy of Science, USA
"We are extremely pleased to have the active participation of such a distinguished and accomplished group of scientific advisors, with extensive expertise in the field of nanoparticles, immunology, and drug development" said Robert Bratzler, PhD, Executive Chairman. "We will be working with the members of the Scientific Advisory Board to refine our strategy for our targeted immunomodulatory nanoparticle product development programs."
Selecta Biosciences, Inc. is a venture backed biopharmaceutical company in the Boston area developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Selecta's proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. Selecta's targeted nanoparticles are rationally designed to deliver bioactive molecules to specific immune cells in the body.
Selecta was founded based on complimentary research by three academic pioneers. The advanced particle technology of Professors Robert Langer (MIT) and Omid Farokhzad (Brigham and Women’s Hospital, Harvard Medical School), two leaders in the fields of drug delivery and targeted nanotechnology, have been combined with the insights into the workings of the immune system made by Professor Ulrich von Andrian (Harvard Medical School), a leader in the field of immunology, to enable Selecta’s broad and powerful product platform. Selecta is backed by leading venture capital firms Polaris Venture Partners and Flagship Ventures.